The Effect of CYP2C19*2 (rs4244285) and CYP17 (rs743572) SNPs on Adriamycin and Paclitaxel based Chemotherapy Outcomes in Breast Cancer Patients.
Rashmi A GudurSuresh J BhosaleAnand K GudurShivani R KaleAshwini L MoreKailas D DatkhilePublished in: Asian Pacific journal of cancer prevention : APJCP (2024)
The findings obtained from this study illustrated significant association of CYP2C9*2 (681G>A) polymorphism with adreamicin based chemotherapy induced toxicities and CYP17 (34T>C) polymorphism with paclitaxel induced bodyache and peripheral neuropathy in BC patients.